ArticleCancers2022

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.

Christos Chouaid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.